Tocilizumab Treatment for Microvascular Inflammation and Chronic Active Antibody-mediated Rejection in Kidney Transplantation.

ABSTRACT:

Background

Interleukin-6 (IL-6) is an important driver of humoral immunity and a target for treatment of antibody-mediated rejection (AMR) in kidney transplantation. Data on IL-6 inhibition for treatment of AMR are mixed and their efficacy remains inconclusive. In this retrospective observational study, we investigated the association of monthly tocilizumab infusions with the trajectory of estimated glomerular filtration rate (eGFR) among kidney transplant patients with histologic features of chronic active AMR.

Methods

Through institutional database review, 85 adult kidney transplant patients with histologic features of chronic active AMR treated with monthly tocilizumab 8 mg/kg intravenous infusions were identified. Piecewise linear mixed effects models were fitted to comp

SUBMITTER: Huang E 

PROVIDER: S-EPMC12499727 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature